top of page
The Professional Network for Healthcare Experts
FDA approves Inluriyo plus Verzenio for ESR1-mutated advanced breast cancer
The FDA has approved Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy.
nuaxia
Sep 212 min read
FDA grants accelerated approval to Etcamah combination for ESR1-mutated advanced breast cancer
The FDA has granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for adults with ESR1-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
nuaxia
Sep 82 min read
bottom of page